295 related articles for article (PubMed ID: 29330507)
1. Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation.
Gao L; Wang KX; Zhou YZ; Fang JS; Qin XM; Du GH
Sci Rep; 2018 Jan; 8(1):624. PubMed ID: 29330507
[TBL] [Abstract][Full Text] [Related]
2. A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC.
Wang KX; Chen YP; Lu AP; Du GH; Qin XM; Guan DG; Gao L
J Ethnopharmacol; 2021 Jun; 274():114043. PubMed ID: 33753143
[TBL] [Abstract][Full Text] [Related]
3. An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.
Lu S; Meng Z; Tan Y; Wu C; Huang Z; Huang J; Fu C; Stalin A; Guo S; Liu X; You L; Li X; Zhang J; Zhou W; Zhang X; Wang M; Wu J
BMC Complement Med Ther; 2022 Mar; 22(1):54. PubMed ID: 35236335
[TBL] [Abstract][Full Text] [Related]
4. Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating β-catenin/c-Myc signaling.
Wang KX; Du GH; Qin XM; Gao L
Phytomedicine; 2021 Dec; 93():153781. PubMed ID: 34649212
[TBL] [Abstract][Full Text] [Related]
5. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
[TBL] [Abstract][Full Text] [Related]
6. Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Compound Kushen Injection in Anti-Cancer Effect.
He R; Ou S; Chen S; Ding S
Med Sci Monit; 2020 Jan; 26():e918520. PubMed ID: 31892693
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the pharmacological effects of Compound Kushen injection on MYC-P15-CCND1 signaling pathway in nasopharyngeal carcinoma - An in vitro study.
Wu Z; Wu C; Shi J; Huang Z; Lu S; Tan Y; You R; Hai L; Huang J; Guo S; Gao Y; Jin Z; Tao X; You L; Wu J
J Ethnopharmacol; 2023 Oct; 315():116702. PubMed ID: 37257705
[TBL] [Abstract][Full Text] [Related]
8. Fractional Deletion of Compound Kushen Injection Indicates Cytokine Signaling Pathways are Critical for its Perturbation of the Cell Cycle.
Aung TN; Nourmohammadi S; Qu Z; Harata-Lee Y; Cui J; Shen HY; Yool AJ; Pukala T; Du H; Kortschak RD; Wei W; Adelson DL
Sci Rep; 2019 Oct; 9(1):14200. PubMed ID: 31578346
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Compound Kushen Injection for the treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation.
Zhang LH; Zhang WY; Xiong JM; Duan XM; Hai LN; Zhang YL; Zhang MM; Qin GF; Zhang GW
Chin J Nat Med; 2022 Jan; 20(1):43-53. PubMed ID: 35101249
[TBL] [Abstract][Full Text] [Related]
10. Identification of the molecular targets and mechanisms of compound mylabris capsules for hepatocellular carcinoma treatment through network pharmacology and bioinformatics analysis.
Wei J; Ma L; Liu W; Wang Y; Shen C; Zhao X; Zhao C
J Ethnopharmacol; 2021 Aug; 276():114174. PubMed ID: 33932512
[TBL] [Abstract][Full Text] [Related]
11. Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine.
Liang S; Li Y; Zhang X; Guo Y; Pan S
Anticancer Agents Med Chem; 2021; 21(15):2012-2022. PubMed ID: 33573576
[TBL] [Abstract][Full Text] [Related]
12. A UPLC-Q-TOF/MS-based plasma metabolomics approach reveals the mechanism of Compound Kushen Injection-based intervention against non-small cell lung cancer in Lewis tumor-bearing mice.
Wu H; Wang L; Zhan X; Wang B; Wu J; Zhou A
Phytomedicine; 2020 Jun; 76():153259. PubMed ID: 32534358
[TBL] [Abstract][Full Text] [Related]
13. A systematic approach to decode the mechanism of Cornus in the treatment of hepatocellular carcinoma (HCC).
Shen HY; Li XQ; Fan WQ; Wang YW; Huang F; Wu JQ; Zhang W; Feng XS; Chao X
Eur J Pharmacol; 2021 Oct; 909():174405. PubMed ID: 34384755
[TBL] [Abstract][Full Text] [Related]
14. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
Qian L; Liu Y; Xu Y; Ji W; Wu Q; Liu Y; Gao Q; Su C
Cancer Lett; 2015 Nov; 368(1):126-134. PubMed ID: 26259512
[TBL] [Abstract][Full Text] [Related]
15. Ardipusilloside inhibits survival, invasion and metastasis of human hepatocellular carcinoma cells.
Lou L; Ye W; Chen Y; Wu S; Jin L; He J; Tao X; Zhu J; Chen X; Deng A; Wang J
Phytomedicine; 2012 May; 19(7):603-8. PubMed ID: 22349030
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics.
Qu Z; Cui J; Harata-Lee Y; Aung TN; Feng Q; Raison JM; Kortschak RD; Adelson DL
Oncotarget; 2016 Oct; 7(40):66003-66019. PubMed ID: 27602759
[TBL] [Abstract][Full Text] [Related]
17. Study on the mechanisms of compound Kushen injection for the treatment of gastric cancer based on network pharmacology.
Zhou W; Wu J; Zhu Y; Meng Z; Liu X; Liu S; Ni M; Jia S; Zhang J; Guo S
BMC Complement Med Ther; 2020 Jan; 20(1):6. PubMed ID: 32020871
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle, energy metabolism and DNA repair pathways in cancer cells are suppressed by Compound Kushen Injection.
Cui J; Qu Z; Harata-Lee Y; Nwe Aung T; Shen H; Wang W; Adelson DL
BMC Cancer; 2019 Jan; 19(1):103. PubMed ID: 30678652
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in Hepatocellular carcinoma and proteomic analysis.
Fu WM; Zhang JF; Wang H; Tan HS; Wang WM; Chen SC; Zhu X; Chan TM; Tse CM; Leung KS; Lu G; Xu HX; Kung HF
Apoptosis; 2012 Aug; 17(8):842-51. PubMed ID: 22610480
[TBL] [Abstract][Full Text] [Related]
20. An Advanced Systems Pharmacology Strategy Reveals
Zhou W; Wu C; Zhao C; Huang Z; Lu S; Fan X; Tan Y; Stalin A; You R; Liu X; Zhang J; Wu Z; Wu J
Front Cell Dev Biol; 2021; 9():742421. PubMed ID: 34646828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
